Cost-Effectiveness Analysis of Smoking Cessation Interventions in Japan Using a Discrete-Event Simulation

Ataru Igarashi, Rei Goto, Kiyomi Suwa, Reiko Yoshikawa, Alexandra J. Ward, Jörgen Moller

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Smoking cessation medications have been shown to yield higher success rates and sustained abstinence than unassisted quit attempts. In Japan, the treatments available include nicotine replacement therapy (NRT) and varenicline; however, unassisted attempts to quit smoking remain common. Objective: The objective of this study was to compare the health and economic consequences in Japan of using pharmacotherapy to support smoking cessation with unassisted attempts and the current mix of strategies used. Methods: A discrete-event simulation that models lifetime quitting behaviour and includes multiple quit attempts (MQAs) and relapses was adapted for these analyses. The risk of developing smoking-related diseases is estimated based on the duration of abstinence. Data collected from a survey conducted in Japan were used to determine the interventions selected by smokers initiating a quit attempt and the time between MQAs. Direct and indirect costs are assessed (expressed in 2014 Japanese Yen). Results: Using pharmacotherapy (NRT or varenicline) to support quit attempts proved to be dominant when compared with unassisted attempts or the current mix of strategies (most are unassisted). The results of stratified analyses by age imply that smoking cessation improves health outcomes across all generations. Indirect costs due to premature death leading to lost wages are an important component of the total costs, exceeding the direct medical cost estimates. Conclusions: Increased utilisation of smoking cessation pharmacotherapy to support quit attempts is predicted to lead to an increase in the number of smokers achieving abstinence, and provide improvements in health outcomes over a lifetime with no additional costs.

Original languageEnglish
Pages (from-to)77-87
Number of pages11
JournalApplied Health Economics and Health Policy
Volume14
Issue number1
DOIs
Publication statusPublished - 2016 Feb 1
Externally publishedYes

Fingerprint

Smoking Cessation
Cost-Benefit Analysis
Japan
Costs and Cost Analysis
Nicotine
Drug Therapy
Health
Smoking
Premature Mortality
Salaries and Fringe Benefits
Therapeutics
Economics
Discrete event simulation
Smoking cessation
Quits
Cost-effectiveness analysis
Recurrence
Abstinence
Varenicline

ASJC Scopus subject areas

  • Economics and Econometrics
  • Health Policy

Cite this

Cost-Effectiveness Analysis of Smoking Cessation Interventions in Japan Using a Discrete-Event Simulation. / Igarashi, Ataru; Goto, Rei; Suwa, Kiyomi; Yoshikawa, Reiko; Ward, Alexandra J.; Moller, Jörgen.

In: Applied Health Economics and Health Policy, Vol. 14, No. 1, 01.02.2016, p. 77-87.

Research output: Contribution to journalArticle

Igarashi, Ataru ; Goto, Rei ; Suwa, Kiyomi ; Yoshikawa, Reiko ; Ward, Alexandra J. ; Moller, Jörgen. / Cost-Effectiveness Analysis of Smoking Cessation Interventions in Japan Using a Discrete-Event Simulation. In: Applied Health Economics and Health Policy. 2016 ; Vol. 14, No. 1. pp. 77-87.
@article{310a1b8c1bc542a6b57751d259d3d4bf,
title = "Cost-Effectiveness Analysis of Smoking Cessation Interventions in Japan Using a Discrete-Event Simulation",
abstract = "Background: Smoking cessation medications have been shown to yield higher success rates and sustained abstinence than unassisted quit attempts. In Japan, the treatments available include nicotine replacement therapy (NRT) and varenicline; however, unassisted attempts to quit smoking remain common. Objective: The objective of this study was to compare the health and economic consequences in Japan of using pharmacotherapy to support smoking cessation with unassisted attempts and the current mix of strategies used. Methods: A discrete-event simulation that models lifetime quitting behaviour and includes multiple quit attempts (MQAs) and relapses was adapted for these analyses. The risk of developing smoking-related diseases is estimated based on the duration of abstinence. Data collected from a survey conducted in Japan were used to determine the interventions selected by smokers initiating a quit attempt and the time between MQAs. Direct and indirect costs are assessed (expressed in 2014 Japanese Yen). Results: Using pharmacotherapy (NRT or varenicline) to support quit attempts proved to be dominant when compared with unassisted attempts or the current mix of strategies (most are unassisted). The results of stratified analyses by age imply that smoking cessation improves health outcomes across all generations. Indirect costs due to premature death leading to lost wages are an important component of the total costs, exceeding the direct medical cost estimates. Conclusions: Increased utilisation of smoking cessation pharmacotherapy to support quit attempts is predicted to lead to an increase in the number of smokers achieving abstinence, and provide improvements in health outcomes over a lifetime with no additional costs.",
author = "Ataru Igarashi and Rei Goto and Kiyomi Suwa and Reiko Yoshikawa and Ward, {Alexandra J.} and J{\"o}rgen Moller",
year = "2016",
month = "2",
day = "1",
doi = "10.1007/s40258-015-0204-3",
language = "English",
volume = "14",
pages = "77--87",
journal = "Applied Health Economics and Health Policy",
issn = "1175-5652",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Cost-Effectiveness Analysis of Smoking Cessation Interventions in Japan Using a Discrete-Event Simulation

AU - Igarashi, Ataru

AU - Goto, Rei

AU - Suwa, Kiyomi

AU - Yoshikawa, Reiko

AU - Ward, Alexandra J.

AU - Moller, Jörgen

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Background: Smoking cessation medications have been shown to yield higher success rates and sustained abstinence than unassisted quit attempts. In Japan, the treatments available include nicotine replacement therapy (NRT) and varenicline; however, unassisted attempts to quit smoking remain common. Objective: The objective of this study was to compare the health and economic consequences in Japan of using pharmacotherapy to support smoking cessation with unassisted attempts and the current mix of strategies used. Methods: A discrete-event simulation that models lifetime quitting behaviour and includes multiple quit attempts (MQAs) and relapses was adapted for these analyses. The risk of developing smoking-related diseases is estimated based on the duration of abstinence. Data collected from a survey conducted in Japan were used to determine the interventions selected by smokers initiating a quit attempt and the time between MQAs. Direct and indirect costs are assessed (expressed in 2014 Japanese Yen). Results: Using pharmacotherapy (NRT or varenicline) to support quit attempts proved to be dominant when compared with unassisted attempts or the current mix of strategies (most are unassisted). The results of stratified analyses by age imply that smoking cessation improves health outcomes across all generations. Indirect costs due to premature death leading to lost wages are an important component of the total costs, exceeding the direct medical cost estimates. Conclusions: Increased utilisation of smoking cessation pharmacotherapy to support quit attempts is predicted to lead to an increase in the number of smokers achieving abstinence, and provide improvements in health outcomes over a lifetime with no additional costs.

AB - Background: Smoking cessation medications have been shown to yield higher success rates and sustained abstinence than unassisted quit attempts. In Japan, the treatments available include nicotine replacement therapy (NRT) and varenicline; however, unassisted attempts to quit smoking remain common. Objective: The objective of this study was to compare the health and economic consequences in Japan of using pharmacotherapy to support smoking cessation with unassisted attempts and the current mix of strategies used. Methods: A discrete-event simulation that models lifetime quitting behaviour and includes multiple quit attempts (MQAs) and relapses was adapted for these analyses. The risk of developing smoking-related diseases is estimated based on the duration of abstinence. Data collected from a survey conducted in Japan were used to determine the interventions selected by smokers initiating a quit attempt and the time between MQAs. Direct and indirect costs are assessed (expressed in 2014 Japanese Yen). Results: Using pharmacotherapy (NRT or varenicline) to support quit attempts proved to be dominant when compared with unassisted attempts or the current mix of strategies (most are unassisted). The results of stratified analyses by age imply that smoking cessation improves health outcomes across all generations. Indirect costs due to premature death leading to lost wages are an important component of the total costs, exceeding the direct medical cost estimates. Conclusions: Increased utilisation of smoking cessation pharmacotherapy to support quit attempts is predicted to lead to an increase in the number of smokers achieving abstinence, and provide improvements in health outcomes over a lifetime with no additional costs.

UR - http://www.scopus.com/inward/record.url?scp=84958111727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958111727&partnerID=8YFLogxK

U2 - 10.1007/s40258-015-0204-3

DO - 10.1007/s40258-015-0204-3

M3 - Article

C2 - 26597111

AN - SCOPUS:84958111727

VL - 14

SP - 77

EP - 87

JO - Applied Health Economics and Health Policy

JF - Applied Health Economics and Health Policy

SN - 1175-5652

IS - 1

ER -